Datasheet

IL-31 Antibody
CATALOG NUMBER: 3745

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Mouse
TESTED APPLICATIONS:ELISA, IHC-P, WB
APPLICATIONS:IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 - 10 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.

Antibody validated: Western Blot in mouse samples and Immunohistochemistry in rat samples. All other applications and species not yet tested.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1283 - RAW 264.7 Cell Lysate
 2) Cat. No. 1467 - Rat Skeletal Muscle Tissue Lysate
IMMUNOGEN:IL-31 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of mouse IL-31.

The immunogen is located within amino acids 30 - 80 of IL-31.
HOST SPECIES:Rabbit

Properties

PURIFICATION:IL-31 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:IL-31 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:IL-31 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:IL-31 Antibody: 1700013B14Rik, Interleukin-31, IL-31
ACCESSION NO.:AAS82846
PROTEIN GI NO.:46241139
OFFICIAL SYMBOL:Il31
GENE ID:76399

Background

BACKGROUND:IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
REFERENCES: 1) Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004; 5:752-60.
2) Dreuw A, Radtke S, Pflanz S, et al. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J. Biol. Chem. 2004; 279:36112-20.
3) Diveu C, Lak-Hal AH, Froger J, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur. Cytokine Netw. 2004; 15:291-302.
4) Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2006; 117:418-25.

For Research Use Only